Aigh Capital Management LLC Medicenna Therapeutics Corp. Transaction History

Aigh Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.44 - $0.82 $3,080 - $5,740	-7,000 Reduced 0.16%	4,339,983 $2.08 Million
Q4 2022 Feb 14, 2023	BUY	$0.4 - $0.68 $198,731 - $337,843	496,829 Added 12.9%	4,346,983 $2 Million
Q3 2022 Nov 10, 2022	BUY	$0.83 - $1.78 $1.31 Million - $2.81 Million	1,577,454 Added 69.41%	3,850,154 $3.19 Million
Q1 2022 May 12, 2022	BUY	$1.26 - $1.92 $73,584 - $112,128	58,400 Added 2.64%	2,272,700 $2.91 Million
Q4 2021 Feb 10, 2022	BUY	$1.53 - $2.85 $1.99 Million - $3.7 Million	1,299,300 Added 142.0%	2,214,300 $3.61 Million
Q2 2021 Aug 12, 2021	BUY	$2.97 - $4.28 $222,750 - $321,000	75,000 Added 8.93%	915,000 $2.77 Million
Q1 2021 May 13, 2021	BUY	$3.5 - $4.56 $2.94 Million - $3.83 Million	840,000 New	840,000 $3.43 Million

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Aigh Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aigh Capital Management LLC with notifications on news.